A broad-ranging new Journal of Infectious Diseases (JID) supplement has been published, offering one of the most comprehensive updates in recent years on the rapidly evolving field of influenza therapeutics
A new Journal of Infectious Diseases (JID) supplement has been published
The collection brings together cutting-edge research, expert reviews and practical insights that span the full spectrum of influenza prevention, treatment and preparedness. Read the supplement.
What the supplement covers
The supplement explores the latest advances across the entire therapeutic landscape, including:
- Antivirals in current use and those progressing through early and late clinical development
- Monoclonal antibodies and immunomodulators
- Drug resistance trends and surveillance
- Therapeutic approaches for high priority and vulnerable populations
It also addresses key connected areas such as:
- Clinical trial design and ongoing for hospitalised influenza patients
- Emerging diagnostic tools and their application
- Pandemic preparedness
- Strategies for optimising antiviral deployment during outbreaks
The result is a rich, multidimensional overview of where the field stands and where it is heading.
How the supplement came together
JID approached Fred Hayden in September 2024 to propose a supplement topic. He responded with a therapeutics focused concept that quickly expanded. What began as a plan for 10 articles ultimately became a 17 article collection, reflecting the depth of expertise and volume of new developments in the field.
Each article underwent:
- Initial review by supplement editors Fred Hayden and Prof Richard Whitley
- Subsequent independent peer review by external reviewers selected by the JID editor-in-chief
To ensure full open access and broad reach, the editors secured funding to cover JID review and Oxford University Press publication costs. Support came from WHO, FluLab, ISRV and several industry partners, highlighting the shared commitment to advancing influenza therapeutics.
Why this matters for ISRV members
For ISRV members, the supplement serves as an integrated, up to date resource bringing together the latest science and clinical thinking. It spans both discovery and real world application, including:
- Pandemic and seasonal influenza
- Zoonotic infections
- Immunocompromised populations
- Paediatric care
This makes it a valuable tool for:
- Clinicians seeking current treatment insights
- Researchers tracking emerging therapeutic avenues
- Students and early career scientists building their knowledge
- Anyone involved in preparedness and response planning
The supplement also highlights the ISRV’s role in promoting scientific collaboration and driving progress across the respiratory virus field.
Read more
